Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: A review

American Journal on Addictions

Volumn 19, Issue 1, 2010, Pages 4-16

  McCance Katz, Elinore F ^a,d   Sullivan, Lynn E ^b   Nallani, Srikanth ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^d SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANXIOLYTIC AGENT; ATAZANAVIR; BUPRENORPHINE; CIPROFLOXACIN; CLARITHROMYCIN; DARUNAVIR; DELAVIRDINE; DESIPRAMINE; DIDANOSINE; DULOXETINE; EFAVIRENZ; FLUCONAZOLE; FLUOXETINE; FLUVOXAMINE; FOSAMPRENAVIR; INTERFERON; LOPINAVIR; METHADONE; NELFINAVIR; NEUROLEPTIC AGENT; NEVIRAPINE; OPIATE; QUETIAPINE; RIBAVIRIN; RIFABUTIN; RIFAMPICIN; RITONAVIR; SERTRALINE; UNINDEXED DRUG; ZIDOVUDINE;

ANEMIA; ANXIETY; ARTHRALGIA; COGNITIVE DEFECT; DEPRESSION; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG INTERACTION; DRUG TRAFFIC; DRUG WITHDRAWAL; DYSPHORIA; FATIGUE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; MAINTENANCE THERAPY; MALAISE; MOOD DISORDER; MYALGIA; OPIATE ADDICTION; PRESCRIPTION; REVIEW; SIDE EFFECT; TUBERCULOSIS;

BUPRENORPHINE; CYTOCHROME P-450 CYP2D6; DRUG INTERACTIONS; HUMANS; METHADONE; OPIOID-RELATED DISORDERS; PRESCRIPTION DRUGS; STREET DRUGS; SUBSTANCE-RELATED DISORDERS;

EID: 77149144153     PISSN: 10550496     EISSN: 15210391     Source Type: Journal    
DOI: 10.1111/j.1521-0391.2009.00005.x     Document Type: Review

References (93)

1. Lepakhin VK. Safety of medicines: A guide to detecting and reporting adverse drug reactions. World Health Organization Web site. 2002. Available at : http://whqlibdoc.who.int/hq/2002/WHO-EDM-QSM-2002.2.pdf. Accessed April 3, 2009.
2. Shields LB, Hunsaker III. JC, Corey TS, et al. Methadone toxicity fatalities: A review of medical examiner cases in a large metropolitan area. J Forensic Sci. 2007 52 : 1389 1395.
3. Karan L, McCance-Katz EF. Pharmacokinetics. In : Kosten TR, Gorelick D, Fiellin D, eds. Principles of Addiction Medicine. Philadelphia, PA : Lippincott Williams & Wilkins 2008 : 67 84.
4. Iribarne C, Berthou F, Baird S, et al. Involvement of cytochrome P450 3A4 enzyme in the n-demethylation of methadone in human liver microsomes. Chem Res Toxicol. 1996 9 : 365 373.
5. Iribarne C, Picart D, Dreano Y, et al. Involvement of cytochrome P450 3A4 in n-dealkylation of buprenorphine in human liver microsomes. Life Sci. 1997 60 : 1953 1964.
6. Moody DE, Alburges ME, Parker RJ, et al. The involvement of cytochrome P 450 3A4 in the n-demethylation of l-alpha-acetylmethadol (LAAM), nor LAAM, and methadone. Drug Metab Dispos. 1997 25 : 1347 1353.
7. Gerber JG, Rosenkranz S, Segal Y, et al. Effect of ritonavir/saquinavir on stereoselective pharmacokinetics of methadone: Results of AIDS Clinical Trials Group (ACTG) 401. J Acquir Immune Defic Syndr. 2001 27 : 153 160.
8. Chang Y, Moody DE, McCance-Katz EF. Novel metabolites of buprenorphine in human liver microsomes and human urine. Drug Metab and Dispos. 2006 34 : 440 448.
9. Kharasch ED, Walker A, Whittington D, et al. Methadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity. Drug Alcohol Depend. 2009 101 : 158 168.
10. Kharasch ED, Hoffer C, Whittington D, et al. Methadone pharmacokinetics are independent of cytochrome P4503A (CYP3A) activity and gastrointestinal drug transport: Insights from methadone interactions with ritonavir/indinavir. Anesthesiology. 2009 110 : 660 672.
11. McCance-Katz EF, Jatlow P, Rainey P, et al. Methadone effects on zidovudine (AZT) disposition (ACTG 262). J Acquir Immune Defic Syn Hum Retrovirol. 1998 18 : 435 443.
12. McCance-Katz EF, Price LH, Kosten TR, et al. Cocaethylene: Pharmacology, physiology, and behavioral effects in humans. J Pharm Exp Ther. 1995 274 : 215 223.
13. Rainey PM, Friedland G, McCance-Katz EF, et al. Interaction of methadone with didanosine (ddI) and stavudine (d4T). J Acquir Immune Defic Syn Hum Retrovirol. 2000 24 : 241 248.
14. Obadia Y, Perrin V, Feroni I, et al. Injecting misuse of buprenorphine among French drug users. Addiction. 2001 96 : 267 272.
15. Walsh SL, Preston KL, Stitzer ML, et al. Clinical pharmacology of buprenorphine: Ceiling effects at high doses. Clin Pharmacol Ther. 1994 55 : 569 580.
16. Reynaud M, Petit G, Potard D, Courty P. Six deaths linked to concomitant use of buprenorphine and benzodiazepines. Addiction. 1998 93 : 1385 1392.
17. CDC-NCHSTP-DHAP. HIV/AIDS surveillance Report. 2000. Available at : http://www.cdc.gov/hiv/stats/hasr1202.2000.
18. Kleber HD. Pharmacologic treatments for heroin and cocaine dependence. Am J Addict. 2003 12 (Suppl. S1 S4.
19. McCance-Katz EF. Office based treatment of opioid dependence with buprenorphine. Harv Rev of Psychiatry. 2004 12 : 321 338.
20. Warnke D, Barreto J, Temergen Z. Antiretroviral Drugs. J Clin Pharmacol. 2007 47 1570.
21. Schwartz EL, Brechbühl AB, Kahl P, et al. Pharmacokinetic interactions of zidovudine and methadone in intravenous drug-using patients with HIV infection. J Acquir Immune Defic Syndr. 1992 5 : 619 626.
22. McCance-Katz EF, Rainey PM, Friedland G, et al. Effect of opioid dependence pharmacotherapies on zidovudine disposition. Am J Addictions. 2001 10 : 296 307.
23. Friedland G, Rainey P, Jatlow P, et al. Pharmacokinetics of didanosine from encapsulated enteric coated bead formulation vs chewable tablet formulation in patients on chronic methadone therapy. Paper Presented at: 14th International AIDS Conference July 2002 Barcelona, Spain.
24. Baker J, Rainey PM, Moody DE, et al. Interactions between buprenorphine and antiretrovirals: Nucleo(t)ide reverse transcriptase inhibitors: (NRTI) didanosine, lamivudine, and tenofovir. Am J Addictions. DOI : 10.1111/j.1521-0391.2009.00004.x.
25. Freimuth W. Delavirdine mesylate, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor. Antiviral Chemotherapy. 1996 4 : 279 289.
26. McCance-Katz EF, Rainey P, Smith P, et al. Drug interactions between opioids and antiretroviral medications: Interaction between methadone, LAAM, and delavirdine. Am J Addictions. 2006 15 : 23 34.
27. Bruce RD, Altice FL. Three case reports of a clinical pharmacokinetic interaction with buprenorphine and atazanavir plus ritonavir. AIDS. 2006 20 : 783 784.
28. McCance-Katz EF, Moody DE, Morse GD, et al. Interaction between buprenorphine and atazanavir or atazanavir/ritonavir. Drug Alcohol Depend. 2007 91 : 269 278.
29. Back D, Gibbons S, Khoo S. Pharmacokinetic drug interactions with nevirapine. J Acquir Immune Defic Syndr. 2003 34 (Suppl 1 S8 14.
30. McCance-Katz EF, Gourevitch MN, Arnsten J, et al. Modified directly observed therapy (MDOT) for injection drug users with HIV disease. Am J Addictions. 2002 11 : 271 278.
31. Boffito M, Rossati A, Reynolds HE, et al. Undefined duration of opiate withdrawal induced by efavirenz in drug users with HIV infection and undergoing chronic methadone treatment. AIDS Res Hum Retroviruses. 2002 18 : 341 342.
32. McCance-Katz EF, Rainey P, Friedland G, et al. The protease inhibitor lopinavir/ritonavir may produce opiate withdrawal in methadone-maintained patients. Clin Infect Dis. 2003 37 : 476 482.
33. McCance-Katz EF. Treatment of opioid dependence and HIV/HCV co-infection in opioid dependent patients: The importance of drug interactions between opioids and antiretroviral medications. Clin Infect Dis. 2005 41 : S89 S95.
34. McCance-Katz EF, Moody DE, Morse G, et al. Interactions between buprenorphine and antiretrovirals I: Non-nucleoside reverse transcriptase inhibitors I: Efavirenz and delavirdine. Clin Infect Dis. 2006 43 (Suppl 4 S224 S234.
35. McCance-Katz EF, Moody DE, Morse G, et al. Interactions between buprenorphine and antiretrovirals II: Protease inhibitors, nelfinavir, lopinavir/ritonavir, or ritonavir. Clin Infect Dis. 2006 43 (Suppl 4 S235 S246.
36. McCance-Katz EF, Moody DE, Morse GD, et al. Lack of clinically significant drug interactions between nevirapine and buprenorphine. DOI : 10.1111/j.1521-0391.2009.00006.x.
37. Cone E, Gorodetzky C, Yousefnejad D, et al. The metabolism and excretion of buprenorphine in humans. Drug Metab. Dispos. 1984 12 : 577 581.
38. Kreek MJ, Garfield JW, Gutjahr CL. Rifampin-induced methadone withdrawal. N Engl J Med. 1976 294 : 1104 1106.
39. McCance-Katz EF. Drug Interactions between Opioids and Infectious Disease Therapeutics: Why Should We Care American Society of Addiction Medicine Annual Meeting NIDA Symposium. New Orleans, LA, April 2009.
40. Brown LS, Sawyer RC, Li R, Cobb MN, et al. Lack of a pharmacologic interaction between rifabutin and methadone in HIV-infected former injecting drug users. Drug Alcohol Depend. 1996 43 : 71 77.
41. Wen X, Wang JS, Neuvonen PJ, et al. Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes. Eur J Clin Pharmacol. 2002 57 : 799 804.
42. Sulkowski MS, Mast EE, Seeff LB, et al. Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus. Clin Infect Dis. 2000 Sup 1 S77 S84.
43. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001 345 : 41 52.
44. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology. 2002 36 : 5237 5244.
45. Berk SI, Litwin AH, Arnsten JH, et al. Effects of pegylated interferon alfa-2b on the pharmacokinetic and pharmacodynamic properties of methadone: A prospective, nonrandomized, crossover study in patients coinfected with hepatitis C and HIV receiving methadone maintenance treatment. Clin Ther. 2007 29 : 131 138.
46. Gupta SK, Sellers E, Somoza E, et al. The effect of multiple doses of peginterferon alfa-2b on the steady-state pharmacokinetics of methadone in patients with chronic hepatitis C undergoing methadone maintenance therapy. J Clin Pharmacol. 2007 47 : 604 612.
47. Fluconazole. In : Physician's Desk Reference, 59th ed. Montvale, NJ : Thomson 2005 : 2480.
48. Voriconazole. In : Physician's Desk Reference, 59th ed. Montvale, NJ : Thomson 2005.
49. Karin H, Segerdahi M, Gustafsson LL, Kalso E. Methadone, ciprofloxacin and adverse drug reactions. Lancet. 2000 356 : 2069 2070.
50. Biaxin. In : Physicians' Desk Reference, 63rd ed., Montvale, NJ : Thomson 2009 : 411 419.
51. Brooner RK, King VL, Kidorf MS, et al. Psychiatric and substance use comorbidity among treatment-seeking opioid abusers. Arch Gen Psychiatry. 1997 54 : 71 80.
52. Kosten TR, Rounsaville BJ, Kleber HD. A 2.5-year follow-up of depression, life crises, and treatment effects on abstinence among opioid addicts. Arch Gen Psychiatry. 1986 43 : 733 738.
53. Iribarne C, Picart D, Dréano Y, et al. In vitro interactions between fluoxetine or fluvoxamine and methadone or buprenorphine. Fundam Clin Pharmacol. 1998 2 : 94 199.
54. Bertschy G, Eap CB, Powell K, et al. Fluoxetine addition to methadone in addicts: Pharmacokinetic aspects. Ther Drug Monit. 1996 18 : 570 572.
55. Bertschy G, Baumann P, Eap CB, et al. Probable metabolic interaction between methadone and fluvoxamine in addict patients. Ther Drug Monit. 1994 16 : 42 45.
56. Hamilton SP, Nunes EV, Janal M, et al. The effect of sertraline on methadone plasma levels in methadone-maintenance patients. Am J Addict. 2000 9 : 63 69.
57. Baumann P. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996 31 : 444 469.
58. Dvir Y, Smallwood P. Serotonin syndrome: A complex but easily avoidable condition. Gen Hosp Psychiatry. 2008 30 : 284 287.
59. Gore M, Sadosky A, Leslie D, et al. Selecting an appropriate medication for treating neuropathic pain in patients with diabetes: A study using the U.K. and Germany Mediplus databases. Pain Pract. 2008 8 : 253 262.
60. Bomsien S, Skopp G. An in vitro approach to potential methadone metabolic-inhibition interactions. Eur J Clin Pharmacol. 2007 63 : 821 827.
61. Di YM, Li CG, Xue CC, et al. Clinical drugs that interact with St. John's wort and implication in drug development. Curr Pharm Des. 2008 14 : 1723 1742.
62. Uehlinger C, Crettol S, Chassot P, et al. Increased (R)-methadone plasma concentrations by quetiapine in cytochrome P450s and ABCB1 genotyped patients. J Clin Psychopharmacol. 2007 27 : 273 278.
63. White JM, Irvine RJ. Mechanisms of fatal opioid overdose. Addiction. 1999 94 : 973 974.
64. Preston KL, Griffiths RR, Cone EJ, et al. Diazepam and methadone blood levels following concurrent administration of diazepam and methadone. Drug Alcohol Depend. 1986 18 : 192 202.
65. Lintzeris N, Mitchell TB, Bond AJ, et al. Pharmacodynamics of diazepam co-administered with methadone or buprenorphine under high dose conditions in opioid dependent patients. Drug Alcohol Depend. 2007 91 : 187 194.
66. Lintzeris N, Mitchell TB, Bond A, et al. Interactions on mixing diazepam with methadone or buprenorphine in maintenance patients. J Clin Psychopharmacol. 2006 26 : 274 283.
67. Rogers WO, Hall MA, Brissie RM, et al. Detection of alprazolam in three cases of methadone/benzodiazepine overdose. J Forensic Sci. 1997 42 : 155 156.
68. Nielsen S, Dietze P, Lee N, et al. Concurrent buprenorphine and benzodiazepines use and self-reported opioid toxicity in opioid substitution treatment. Addiction. 2007 102 : 616 622.
69. Mégarbane B, Hreiche R, Pirnay S, et al. Does high-dose buprenorphine cause respiratory depression?: Possible mechanisms and therapeutic consequences. Toxicol Rev. 2006 25 : 79 85.
70. Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol. 2006 61 : 246 255.
71. Sharma A, Hamelin BA. Classic histamine H1 receptor antagonists: A critical review of their metabolic and pharmacokinetic fate from a bird's eye view. Curr Drug Metab. 2003 4 : 105 129.
72. Ereshefsky L, Riesenman C, Lam YW. Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6. Clin Pharmacokinet. 1995 29 (Suppl 1 10 18.
73. Maany I, Dhopesh V, Arndt IO, et al. Increase in desipramine serum levels associated with methadone treatment. Am J Psychiatry. 1989 146 : 1611 1613.
74. Lotrich FE, Rosen J, Pollock BG. Dextromethorphan-induced delirium and possible methadone interaction. Am J Geriatr Pharmacother. 2005 3 : 17 20.
75. Gupta JD, Gruca M, Ablett W. Effect of other drugs and chemicals on the degradation of aspirin in vitro: Possible extrapolation to in vivo metabolism of aspirin. Eur J Drug Metab Pharmacokinet. 1979 4 : 103 108.
76. McCance-Katz EF, Rainey PM, Moody DE. Effect of cocaine use on buprenorphine pharmacokinetics in humans. Am J Addictions. DOI : 10.1111/j.1521-0391.2009.00001.x.
77. Pellinen P, Stenbäck F, Kojo A, et al. Regenerative changes in hepatic morphology and enhanced expression of CYP2B10 and CYP3A during daily administration of cocaine. Hepatology. 1996 23 : 515 523.
78. Lopez P, Velez R, Rivera V. Characteristics of P-glycoprotein (Pgp) upregulated in chronic cocaine users and HIV infected persons. Retrovirology. 2005 2 (Suppl 1 142.
79. Madden JA, Konkol RJ, Keller PA, et al. Cocaine and benzoylecgonine constrict cerebral arteries by different mechanisms. Life Sci. 1995 56 : 679 686.
80. Fiellin DA, Sullivan L, Moore BC, et al. The impact of cocaine use on outcomes in office-based buprenorphine treatment [abstract College on Problems of Drug Dependence, 2008 San Juan, PR.
81. McCance-Katz EF, Jatlow P, Rainey PM. Effect of cocaine use on methadone pharmacokinetics in humans. Am J Addictions. DOI : 10.1111/j.1521-0391.2009. 00009.x.
82. Nemoto T. Patterns of cocaine use and HIV infection among injection drug users in a methadone clinic. J Subst Abuse. 1994 6 : 169 178.
83. Foltin RW, Fischman MW. Effects of buprenorphine on the self-administration of cocaine by humans. Behav Pharmacol. 1994 5 : 79 89.
84. Kreek MJ. Opioid interactions with alcohol. Adv Alcohol Subst Abuse. 1984 3 : 35 46.
85. Kreek MJ. Metabolic interactions between opiates and alcohol. Ann N Y Acad Sci. 1981 362 : 36 49.
86. Krantz MJ, Martin J, Stimmel B, et al. QTc Interval screening in methadone treatment. Ann Intern Med. 2009 150 : 387 395.
87. Krantz MJ, Kutinsky IB, Robertson AD, et al. Dose-related effects of methadone on QT prolongation in a series of patients with torsades de pointes. Pharmacotherapy. 2003 23 : 802 805.
88. Lüthi B, Huttner A, Speck RF, et al. Methadone-induced torsade de pointes after stopping lopinavir-ritonavir. Eur J Clin Microbiol Infect Dis. 2007 26 : 367 369.
89. Baker JR, Best AM, Pade PA, et al. Effect of buprenorphine and antiretroviral agents on the QT interval in opioid-dependent patients. Ann Pharmacother. 2006 40 : 392 396.
90. Atazanavir (Reyataz) Product Label. http://www.accessdata.fda.gov/ drugsatfda-docs/label/2006/021567s007lbl.pdf. Accessed June 3, 2009.
91. Darunavir (Prezista) Product Label. http://www.fda.gov/cder/foi/label/ 2008/021976s009lbl.pdf. Accessed June 3, 2009.
92. Fosamprenavir (Lexiva) Product Label. http://www.fda.gov/cder/foi/label/ 2008/021548s017,022116s001lbl.pdf. Accessed June 3, 2009.
93. Nelfinavir (Viracept) Product Label. http://www.fda.gov/cder/foi/label/ 2008/020778s029,020779s050,021503s011lbl.pdf. Accessed June 3, 2009.